Evidence map›Paper›PMID 39747775›Full record

ReviewInvestigational new drugs2025

Immunotherapy in thymic epithelial tumors: an attractive dilemma.

Nahed Damaj, Dany Nassar, Bilal Chamaa, Joseph Kattan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Investigational new drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nahed DamajDepartment of Hematology-Oncology, Faculty of Medicine, Hôtel Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon. nahed.damaj@outlook.com.
Dany NassarDepartment of Hematology-Oncology, Faculty of Medicine, Hôtel Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon.
Bilal ChamaaDepartment of General Surgery, Faculty of Medicine, Hôtel Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon.
Joseph KattanDepartment of Hematology-Oncology, Faculty of Medicine, Hôtel Dieu de France University Hospital, Saint Joseph University of Beirut, Beirut, Lebanon.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymomas and thymic carcinomas are the most prevalent tumors that develop in the thymus's epithelial tissue. Thymomas are malignant tumors that develop from the epithelial cells of the thymus and frequently include mixed populations of lymphocytes. In contrast, thymic carcinomas are also tumors of the thymic epithelium, but they are characterized by a lack of lymphocytes, exhibit more aggressive behavior, and are associated with a poorer prognosis. Surgical intervention is the primary approach for managing resectable cases, while advanced, unresectable tumors are treated with platinum-based chemotherapy. The recurrence of the disease can happen months to years after initial treatment. Some patients do benefit from biologic therapies, but there is still a significant need for new treatment options. Immune checkpoint inhibitors have proven safe and clinically effective, improving survival in various cancers. However, their use in thymic cancers is currently limited to treating recurrent thymic carcinoma due to potential immune toxicity risks. This manuscript reviews the current applications of immunotherapy for thymic epithelial tumors and discusses strategies to enhance safety and expand treatment options for patients with these cancers.

Indexed as

Immune Checkpoint InhibitorsImmunotherapyNeoplasms, Glandular and EpithelialThymus NeoplasmsHumansImmune Checkpoint InhibitorsImmune checkpoint inhibitorsImmunotherapyThymic carcinomaThymoma

Identifiers

PMID39747775

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.